Glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) are examples of incretin hormones released from neuroendocrine cells of the gastrointestinal tract into the circulation after a meal. GLP-1RAs maintain...
The examples include inhibitors of sugar transporters (SGLT2 inhibitors) that are successfully used in patients with kidney disease, diabetes or heart failure. Likewise, indirect inhibitors (acetazolamide) of an transporter absorbing sodium in exchange for protons (NHE3) are used most...
In addition to diet and exercise, SGLT2 inhibitors, a class of FDA-approved prescription medications, are used to lower blood sugar levels in people with Type 2 diabetes. Canagliflozin, dapagliflozin, and empagliflozin are examples of drugs that are SGLT2 inhibitors. Single-ingredient formulations ...
To determine whether canagliflozin mediates its action solely through OxPhos inhibition, we compared its anti-proliferative activity to that of two specific OxPhos complex-I inhibitors, BAY-87-224347and IACS-01075948. At widely used doses, these agents significantly suppressed OCR in glycolytic rate bi...
Originally designed as anti-hyperglycemic drugs, Glucagon-Like Peptide-1 receptor agonists (GLP-1Ra) and Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated protective cardiovascular effects, with significant impact on cardiovascular mor
11 Although examples of carbasugar being reported as a glucose mimetic were limited, those examples have encouraged us to prepare and evaluate carbasugar derivatives as SGLT2 inhibitors (6a–6n).12 Access through your organization Check access to the full text by signing in through your ...
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a new class of oral antidiabetic drugs used in patients with type 2 diabetes (T2DM) as glucose-lowering therapies, but that have important additional benefits for a range of clinical indications even without T2DM; especially for other morbidit...
[00821 Examples of antihyperuricemic agents suitable for use in combination with the crystalline compound of the present invention include uric acid synthesis inhibitors (such as allopurinol, oxypurinol and the like), uricosuric agents (such as probenecid, sulfinpyrazone, benzbromarone and the ...
Examples of the compounds are: (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-(2,2,2- trifluoroethoxy)ethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-(cyclohex-2-enyloxy)ethoxy)benzyl)phenyl)-6-(hydroxymethyl)...
The sodium–glucose cotransporter2 inhibitors, which are commonly used to lower blood sugar levels in people with type2 diabetes, are examples of such drugs. Data from two studies of sodium–glucose cotransporter2 inhibitors—the CREDENCE study of canagliflozin in patients with chronic kidney disease...